Molly Burich

US manufacturers prepare for expanding biosimilar market opportunities as this exciting landscape takes shape. The production of biosimilars poses challenges as pharma looks to curb health care spending.

As health care costs continue to increase, and with high-cost specialty products making up a significant portion of the pipeline, the role of the Specialty Pharmacy (SP) continues to grow and influence health care decisions across multiple stakeholders.